Literature DB >> 7378252

Pharmacokinetics of a sustained-release theophylline formulation.

P W Trembath, S W Boobois.   

Abstract

1 Plasma theophylline concentrations following administration of sustained-release (SR) theophylline tablets were determined in ten healthy volunteers using a dose of 190 mg or 380 mg 12 hourly. 2 The plasma theophylline levels during the first 12 h period confirmed the sustained-release formulation characteristics, with the plasma drug concentrations reaching a plateau for the last 6 hours. 3 During the fifth 12 h dosing period the mean maximum and minimum plasma theophylline concentrations were 7.25 and 4.30 microgram/ml after 190 mg SR theophylline 12 hourly (n = 6) and 12.96 and 7.36 microgram/ml after 380 mg 12 hourly (n = 5), although there was marked between-subject variation in plasma theophylline concentrations. 4 One subject withdrew from the study due to side effects, which were more common when the higher dose of SR theophylline was given.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7378252      PMCID: PMC1429978          DOI: 10.1111/j.1365-2125.1980.tb01063.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Gas-liquid chromatographic determination of theophylline in human plasma.

Authors:  L J Dusci; L P Hackett; I A McDonald
Journal:  J Chromatogr       Date:  1975-01-29

2.  Effect of smoking on theophylline disposition.

Authors:  S N Hunt; W J Jusko; A M Yurchak
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

3.  The influence of cigarette smoking and sex on theophylline disposition.

Authors:  J R Powell; J F Thiercelin; S Vozeh; L Sansom; S Riegelman
Journal:  Am Rev Respir Dis       Date:  1977-07

4.  Comparison of the bioavailability of aminophylline in a conventional base and in a continous-release base.

Authors:  C Boroda; R B Miller; S T Leslie; E G Nicol; I Thomson
Journal:  J Clin Pharmacol       Date:  1973-10       Impact factor: 3.126

5.  A re-evaluation of parenteral aminophylline.

Authors:  D P Nicholson; T W Chick
Journal:  Am Rev Respir Dis       Date:  1973-08

6.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

7.  Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline.

Authors:  J W Jenne; M S Wyze; F S Rood; F M MacDonald
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

8.  The relation of product formulation to absorption of oral theophylline.

Authors:  M Weinberger; L Hendeles; L Bighley
Journal:  N Engl J Med       Date:  1978-10-19       Impact factor: 91.245

9.  Guide to oral theophylline therapy for the treatment of chronic asthma.

Authors:  L Hendeles; M Weinberger; R Wyatt
Journal:  Am J Dis Child       Date:  1978-09
  9 in total
  5 in total

1.  In vitro testing of controlled release theophylline preparations: Theolair, Theograd and Theolin.

Authors:  J P Crombeen; C J De Blaey
Journal:  Pharm Weekbl Sci       Date:  1983-04-29

2.  Well-tempered MCMC simulations for population pharmacokinetic models.

Authors:  Frederic Y Bois; Nan-Hung Hsieh; Wang Gao; Weihsueh A Chiu; Brad Reisfeld
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-07-31       Impact factor: 2.745

3.  Components of variability in serum theophylline concentrations during maintenance therapy with a sustained release formulation.

Authors:  H Halkin; A Mazar; S Almog; Y Schnaps
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers.

Authors:  Janak R Wedagedera; Anthonia Afuape; Siri Kalyan Chirumamilla; Hiroshi Momiji; Robert Leary; Mike Dunlavey; Richard Matthews; Khaled Abduljalil; Masoud Jamei; Frederic Y Bois
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-04-22

5.  A Retrospective Study on the Epidemiological and Clinical Features of Emergency Patients with Large or Massive Consumption of Caffeinated Supplements or Energy Drinks in Japan.

Authors:  Yoshito Kamijo; Michiko Takai; Yuji Fujita; Kiyotaka Usui
Journal:  Intern Med       Date:  2018-03-09       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.